ArticleFrontiers in neurology
How much is enough? Hematoma clearance thresholds and 30-day outcomes after sMIS for ICH across overall and baseline volume strata.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic relevance of hematoma clearance after stereotactic minimally invasive surgery (sMIS) for supratentorial intracerebral hemorrhage (ICH) remains incompletely defined. We evaluated the association between hematoma clearance rate (HCR) and 30-day functional outcome and explored clinically interpretable HCR thresholds. Methods: We retrospectively analyzed 148 consecutive adults with spontaneous supratentorial ICH who underwent frame-based sMIS between January 2020 and December 2024. Preoperative and early postoperative non-contrast CT scans were segmented using 3D Slicer to derive preoperative hematoma volume, postoperative residual hematoma volume, intraoperative aspirated hematoma volume, and HCR. The primary outcome was 30-day unfavorable functional outcome, defined as modified Rankin Scale (mRS) 4-6. Multivariable logistic regression, generalized additive models, ROC analysis, threshold-based diagnostic performance analysis, interaction analysis, and sensitivity analysis were performed. The fully adjusted model included age, admission Glasgow Coma Scale category, preoperative hematoma volume, Barras morphology grade, international normalized ratio, hemoglobin, platelet count, onset-to-surgery time, and postoperative intracavitary thrombolysis. Results: Of 148 patients, 73 achieved mRS 0-3 and 75 had mRS 4-6 at 30 days. Higher HCR was independently associated with lower odds of unfavorable outcome in the fully adjusted model (OR 0.91 per 1% increase, 95% CI 0.86-0.96; Conclusion: HCR after sMIS was independently associated with 30-day functional outcome and may serve as a postoperative prognostic benchmark. An HCR threshold near 60% may help risk stratification after sMIS and may complement absolute residual-volume thresholds such as 15 mL. Prospective multicenter validation is required before this threshold can be used as a prescriptive treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.